Physician profile
Jerome E Scherer
NPI 1881669828
$7,203.62
in general payments reported to CMS, 2019-2025
26 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $735 · 2021: $1,457 · 2022: $1,444 · 2023: $1,376 · 2024: $1,046 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,732.28 | 2019-2025 | Injectafer |
| Novo Nordisk INC | $858.23 | 2019-2025 | Wegovy, Saxenda |
| Glaxosmithkline, LLC. | $788.94 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $692.11 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $299.71 | 2019-2025 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $247.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $237.34 | 2022-2023 | |
| Pfizer INC. | $227.59 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $181.55 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $178.54 | 2019 | |
| Exact Sciences Corporation | $148.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $125.81 | 2019-2024 | Austedo Xr, Ajovy |
| Otsuka America Pharmaceutical, INC. | $78.83 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.62 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $65.43 | 2023 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $53.52 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.79 | 2020-2022 | |
| Sanofi Pasteur INC. | $26.96 | 2019-2020 | |
| Dexcom, INC. | $23.29 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $22.34 | 2024 | Spravato |
| Lundbeck LLC | $18.66 | 2024 | Rexulti |
| Sobi, INC | $17.93 | 2019 | |
| Heartflow, INC. | $17.38 | 2024 | |
| Antares Pharma, INC. | $15.16 | 2022 | |
| Astellas Pharma US INC | $14.60 | 2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Scherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.